肿瘤浸润淋巴细胞在三阴性乳腺癌免疫治疗中的应用进展  

Progress of Tumor Infiltrating Lymphocytes in Immunotherapy of Triple Negative Breast Cancer

作　　者：赵佳琳 王学晶[2] 曹希[2] 孙强[2] ZHAO Jialin;WANG Xuejing;CAO Xi;SUN Qiang(Department of Ultrasound,PUMC Hospital,CAMS and PUMC,Beijing 100730,China;Department of Breast Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院超声医学科,北京100730 [2]中国医学科学院北京协和医学院北京协和医院乳腺外科,北京100730

出　　处：《中国医学科学院学报》2021年第3期475-480,共6页Acta Academiae Medicinae Sinicae

基　　金：北京协和医学院中央高校基本科研业务费专项资金(3332020001)。

摘　　要：乳腺癌已成为中国女性发病率最高的癌症,而三阴性乳腺癌(TNBC)因缺乏有效的治疗靶点,与其他类型乳腺癌相比预后较差。肿瘤浸润淋巴细胞(TILs)是存在于肿瘤周围的一群异质性淋巴细胞,大量研究认为,TILs是宿主免疫系统对肿瘤抗原存在免疫反应的标志。目前已有文献报道TILs对于乳腺癌预后的预测作用,其研究热点主要集中在TNBC上,本文总结了TILs在TNBC免疫治疗中的应用进展。Breast cancer has become the most common cancer for women in China.Lack of effective therapeutic targets,triple negative breast cancer(TNBC)has poorer prognosis compared with other subtypes of breast cancer.Tumor infiltrating lymphocytes(TILs)are a group of heterogeneous lymphocytes around the tumor,which are believed as immunoreactive products of host immune response to tumor antigens.At present,there have been reports on the predictive effect of TILs on the prognosis of breast cancer,and the available studies focus mainly on TNBC.This article briefly reviews the recent progress of tumor infiltrating lymphocytes in immunotherapy of TNBC.

关 键 词：三阴性乳腺癌 肿瘤浸润淋巴细胞 免疫治疗 预后 

分 类 号：R737.9[医药卫生—肿瘤]